Argenx Bounds Off 200-Day Line On 'Best-Case Scenario' For Blockbuster Drug
In This Article:
Argenx stock jumped Friday after the FDA cleared its autoimmune disease drug, Vyvgart Hytrulo, for at-home treatment.
Oops, something went wrong
Argenx stock jumped Friday after the FDA cleared its autoimmune disease drug, Vyvgart Hytrulo, for at-home treatment.